fda warning letters compounded glp-1 september 2025 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of medications like semaglutide and tirzepatide, signaling a major shift in how these FDA calls out Hims and

A primary finding emerged from the Y-maze test, which evaluated recognition memory

MI supplementation restores PI3K/Akt signaling, lowers circulating insulin, and indirectly reshapes the microbial niche by reducing luminal glucose and OS (236)

Clin Exp Optom

Cells were incubated with 1:100 anti-rabbit GLUT1 (Abcam, ab115730) antibody in BD Stain Buffer (BSA) (BD Biosciences) 30 min at room temperature after 20 min on ice to block nonspecific binding, followed by incubation for 30 min at room temperature with 1:200 Alexa Fluor 647 (Abcam, ab150075)

Breast, colon, and kidney cancers are more likely to develop in obese people

GLP-1 Medication Persistence, a Key Component of Weight Loss Medication persistence (remaining on a medication for the prescribed length of time) may be one of the greatest barriers to achieving clinically-meaningful outcomes in obesity management